What are the differences between A1 and A2 blood type donors in liver transplantation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

A1 and A2 Blood Type Donors in Liver Transplantation

Key Distinction

A2 donors can be safely used for O-positive liver transplant recipients, whereas A1 donors are contraindicated due to significantly different antigen expression levels. 1

The critical difference between A1 and A2 blood subtypes lies in their antigen expression:

  • A2 donors express substantially lower levels of A antigens on their tissues compared to A1 donors 1, 2
  • A1 donors have higher A antigen expression that triggers hyperacute rejection and antibody-mediated rejection in O recipients 1

Clinical Application for O Recipients

Safe Donor Options (A2 Subgroup)

A2 liver grafts can be transplanted into O recipients without special immunomodulation protocols or antibody titer restrictions. 3

  • A2 donors behave functionally like O blood type donors due to their diminished antigen expression 4, 2
  • Large registry analysis of 358 A2-to-O liver transplants showed equivalent 5-year overall survival (77% vs 74%) and graft survival (66% vs 66%) compared to O-to-O transplants 5
  • This approach significantly expands the donor pool for O recipients, who face the longest wait times 3

Contraindicated Options (A1 Subgroup)

A1 donors must not be used for O recipients in routine practice due to incompatibility. 1

  • A1 antigens provoke severe antibody-mediated rejection 1
  • Standard ABO-incompatible protocols (used for A1 grafts) require intensive immunosuppression, plasmapheresis, and carry substantially higher risks 2

Important Clinical Caveats

Rejection Risk with A2 Donors

While generally safe, A2-to-O transplantation carries nuanced risks:

  • Higher rates of acute cellular rejection have been observed in some series, with a significant proportion being late (>90 days) or steroid-resistant 3
  • Rare but documented cases of antibody-mediated rejection can occur, even with A2 donors, particularly in A2-to-B transplants 6, 7
  • Serial monitoring of anti-A isohemagglutinin titers post-transplant is prudent, though not universally required 6

No Special Pre-Transplant Requirements

Unlike A2 kidney transplantation, A2 liver transplantation to O recipients does not require:

  • Pre-transplant antibody titer screening 3
  • Plasmapheresis or antibody removal strategies 3
  • Augmented immunosuppression protocols 3

This is due to the liver's unique immunoabsorptive capacity that protects against antibody-mediated injury 7

Practical Algorithm for O Recipients

Priority 1: O-positive or O-negative donors (ABO-identical or compatible) 1

Priority 2: A2 donors when no O donor is available 1, 5

Avoid: A1 donors and AB donors (contraindicated) 1

Emergency situations only: Consider full ABO-incompatible grafts (A1, B, AB) with intensive protocols when no compatible graft exists and death is imminent 1

Rh Factor Consideration

The Rh status (positive/negative) is irrelevant in liver transplantation, as Rh antigens are not expressed on hepatocytes, allowing grafts from both Rh-positive and Rh-negative donors regardless of recipient Rh status 1

References

1
Guideline

ABO Compatibility Guidelines for O‑Positive Liver Transplant Recipients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

2
Research

ABO-incompatibility in solid organ transplantation.

Transfusion medicine (Oxford, England), 2001

6
Research

ABO-Incompatible Living Donor Liver Transplant From a Blood Type A2 Donor to a Type B Recipient: A Note of Caution.

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2022

Related Questions

Can an adult with elevated cholesterol use beetroot to improve lipid levels, and what dosage and duration are recommended?
How frequently should a lipid profile be obtained to monitor dyslipidemia control?
What is the recommended management for a 70-year-old patient with a coronary artery calcium score of 813, an enlarged pulmonary artery, LDL‑cholesterol of 143 mg/dL, and no prior myocardial infarction?
What are the 2026 cholesterol management guidelines, including recommended screening age, risk assessment tools, LDL‑C target levels, and treatment recommendations such as statin intensity, ezetimibe, PCSK9 inhibitors, coronary calcium scoring, and management of elevated triglycerides and lipoprotein(a)?
In a 32-year-old man with dyslipidemia and low high‑density lipoprotein (<30 mg/dL) who was started on rosuvastatin 5 mg and now has nocturnal pruritus after three months, could the itching be caused by rosuvastatin and how should it be managed?
In a diabetic patient, does an incidental finding of moderate vascular calcifications on a foot X‑ray require further work‑up?
Will an abdominal CT scan visualize the ovaries?
What is the appropriate method to transition a patient from propranolol to metoprolol, including dose equivalence, titration, and monitoring?
Is Novolin (human insulin) a long‑acting insulin?
When should I repeat renal laboratory tests (estimated glomerular filtration rate, serum creatinine, potassium, and urine albumin‑to‑creatinine ratio) based on the current albuminuria result?
What does the term A2 donor refer to, and is it a blood group A donor?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.